This paper examines recent risk assessments for benzene and observes a number of inconsistencies within the study and consistencies between studies that should effect the quantitative determination of the risk from benzene exposure. Comparisons across studies show that only acute myeloid leukemia (AML) is found to be consistently in excess with significant benzene exposure. The data from the Pliofilm study that forms the basis of most quantitative assessments reveal that all the AML cases came from only one of the three studied plants and that all the benzene exposure data came from the other plants. Hematological data from the 1940s from the plant from which almost all of the industrial hygiene exposure data come do not correlate well with the originally published exposure estimates but do correlate well with an alternative set of exposure estimates that are much greater than those estimates originally published. Temporal relationships within the study are not consistent with those of other studies. The dose-response relationship is strongly nonlinear. Other data suggest that the leukemogenic effect of benzene is nonlinear and may derive from a threshold toxicity.
Introduction
Quantitative assessments of the carcinogenic (leukemogenic) risk from benzene exposure have been of regulatory importance since the U.S. Supreme Court (1) magnitude of these deviances, while often unclear, can be shown and assessed more clearly by asking similar critical questions of each study to define clearly the underlying assumptions and by testing those underlying assumptions. This paper deals with the concept of consistency among the studies that generally support the concept of an association between benzene exposure and excess risk of leukemia and within the studies critical to the quantitative assessment of that risk. Although the largest studies relating benzene and cases of leukemia are those of Aksoy (2) in Turkey (51 cases), Vigliani (3) in Italy (24 cases), and Yin (4) in China (30 cases), the largest United States study (9 cases) which was conducted by the National Institute for Occupational Safety and Health (NIOSH) (5) serves as the primary basis for the quantitative assessment of leukemia risk from benzene exposure. The findings of the larger studies are compared with the NIOSH study for consistency of findings across studies, and the NIOSH study is examined in detail later in this paper for consistency within the study.
The basic classiflcation of leukemias is reviewed as a prelude to a review of the types of leukemia noted in studies of benzene exposed workers. The critical NIOSH study (6) is then reviewed with respect to the relationship between the leukemia cases and the benzene exposure data presented in the paper. Finally, this paper considers some of the consequences of these observations on the theoretical shape of the dose-response curve between benzene and leukemia.
Observations from the Literature on Benzene and Leukemia
Classification of Lymphomas and Leukemias
In the International Classification of Diseases (ICD-9-ICM) (6) Vigliani reported originally in 1964 (9) and again in 1976 (3) on the benzene and leukemia experience of Italian occupational medicine clinics (Fig. 1) . Twenty-four of 24 cases of leukemia in benzene-exposed workers were AML. Aksoy reported originally in 1974 (10) and again in 1985 (2) on the experience of Turkish shoemakers and leatherworkers with benzene and leukemia (Fig. 2) . Forty-three of 51 cases of leukemia were AML. The NIOSH study of the experience of Ohio Pliofilm rubber workers at two locations with benzene and leukemia ( Fig.  3) case among the seven leukemia cases observed (Fig. 6 ).
Based on the experiences of other benzene-exposed groups, at least four cases of AML would have been expected among the seven leukemia cases. There are a number of other observations from the Wong et al. study where the results are different from other benzene studies. No case of leukemia was observed in their nonbenzene-exposed workforce. Figure 3 presents the cell type distribution of leukemia cases in the most recent report of the NIOSH study of the Ohio Pliofilm rubber workers (5) . Again, AML is the most common type. Six of the nine cases of leukemia reported in the study were AML. Five cases reported were myeloblastic and the sixth was AMoL. The pattern that again stands out is the dominance of AML among the leukemias of benzene-exposed workers.
There are few studies that provide comparative data on the proportion of leukemias expected to be AML in a nonbenzene-exposed worker population. Most population studies show that AML accounts for about one-third of all leukemias, typically ranging from 20 to 40%. The only direct comparison group is found in the study by Aksoy (2) , which reported the leukemia types of 50 cases of leukemia in men seen in the same clinics but lacking known benzene exposure. He reported about equal numbers of each of the 4 types of cases (Fig. 2 ). Aksoy's studies of Turkish shoemakers were interesting because, while professor at the university hematology clinic in Istanbul, he was able to separate out 51 leukemia cases 291 in workers with benzene exposure and 50 leukemia cases in persons without benzene exposure. For those cases that were benzene associated, AML prevailed (84%). For those not exposed to benzene, AML represented only 28% of the leukemia cases. For the nonbenzene-related background leukemias, Aksoy demonstrated a relatively equal representation of AML, ALL, CML, and CLL. AML is the only type that stood out in excess among the benzene-exposed cases compared to the nonbenzeneexposed cases (see Fig. 3 ). Thus, the studies of benzene workers, with 65 to 100% of their leukemia cases diagnosed as AML, quite likely represent an increased risk of AML.
The six studies described present a total of 126 leukemia cases among benzene exposed workers. The percentage distribution of these cases by type of leukemia is shown in Figure 7 , along with expected percentiles based on 1978 US Leukemia Mortality data (20, 21) . There is little exposure information within these studies to group the workers into exposure categories other than the gross category of occupationally exposed to significant amounts of benzene, significantly great enough to be described in the literature as benzene exposed. Figure 7 reveals that when the cases from all six studies are viewed together, only AML stands out in marked excess above the others. This is the epidemiological basis for the conclusion that the acute myeloid leukemias are the only leukemias found in significant excess with significant benzene exposure. Thus, we propose that the distribution of AML among benzene exposed persons should serve as the basis of epidemiological and risk analysis.
We believe estimations of the risk of leukemia from benzene exposure should be based on the AML data, since this neoplastic disease alone has been shown to have an association with benzene exposure. It would be inappropriate to extrapolate the risk of AML to all leukemias when the risk appears to be biologically specific to AML.
In studies where types of leukemia are not stated, analyses may provisionally have to be based on all leukemias, but specific diagnostic data should be obtained before the data are used in risk analysis. Some risk assessments have failed to compare the risks of the same disease between different studies.
Exposure definition and documentation have generally been the weakest aspect of risk assessment. Essentially, only AML is attributable to benzene exposure and other types of leukemia are not. The probability of benzene Other FIGURE 7. Percent distribution of benzene leukemia cases from six studies (n = 126) (13, 14) and of U.S. leukemia deaths, ages 1978 (20, 21) .
causing other leukemias is low, and may be zero. Some scientists disagree. They point to some studies where a nonsignificant excess of CML may be associated with benzene exposure, but they agree that this is not a consistent result. In order to believe that benzene causes CML, one must both explain the lack of consistency between and within studies, and reject the assumption that a given carcinogen produces the same cancer in all people.
Risk Analysis of Benzene and Leukemia
The Ohio Pliofilm study (11) conducted initially by NIOSH through June 1975, reported the leukemia mortality of some grotips of workers employed on the wet side of the benzene-using Pliofilm manufacturing process at three rubber plants in Ohio during the 1940s. Pliofilm was made using natural rubber, processing it by adding benzene to create rubber hydrochloride solution, and eventually spreading the resultant solution on a conveyor. The benzene was evaporated and recovered. A recent update of this study (6) extended the study group to include workers assigned to these areas at the three plants through 1965. The updated study reported the deaths from leukemia and lymphomas that occurred through 1981. aMoL, monocytic leukemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; AMoL, acute monoblastic leukemia; ML, myeloid leukemia; MM, multiple myeloma; PCS, plasma cell sarcoma. (2) have an average latency of 9 years. Thus, the NIOSH data are also unusual with respect to AML latency in comparison to other studies of benzeneassociated leukemias.
The temporal relationship between exposure and disease may also be examined on the basis of the time interval between the date of last exposure and the date of death or diagnosis. An analysis of the literature in 1980 showed that 80% of benzene-associated leukemia deaths occurred no more than two years after their last benzene exposure (18) . The implication of these results is that the risk of leukemia decreases with time after exposure, which suggests that benzene may act at a later stage in the carcinogenic process, perhaps through action on promotion or disease progression.
The idea that benzene is not an initiator is consistent with two other facts: benzene has not caused mutagenic effects at the level of base-pair changes (transitions, short deletions, frame shifts, and so forth) in appropriate shortterm tests, and benzene pancytopenia frequently precedes leukemia. The Chinese study (4) reported a leukemia risk ratio of 1500 for benzene-exposed workers with pancytopenia in comparison with a leukemia risk ratio of 5 to 10 for the total benzene-exposed work force. This observation suggests that pancytopenia may be a necessary precursor or threshold condition in order for benzeneinduced leukemia to Most of the benzene exposures estimated for workers in Pliofilm production occurred during the 1940s, when minimal or no exposure data were collected. The estimation of cumulative benzene exposures for specific individuals is limited to the time they spent in Pliofilm production and is markedly dependent upon the assumptions used to develop their exposure estimates for the 1940s. The work forces at the two plants differed in their potential for exposure to benzene and other chemicals at nonPliofilm job sites. Plants 2A and 2B were part of a large industrial tire-building complex, and plant 1 was isolated in a small town in southern Ohio. Furthermore, the assumptions made regarding exposure levels in the Pliofilm operations in the 1940s are in dispute.
Rinsky et al. (5) assumed that for a given job the exposure levels were constant backward over time unless specific data indicated otherwise. In other words, the exposure levels were assumed to be the same both during the periods for which exposure data existed and during prior periods for which no data existed. Thus, if the only data for a specific job produced an estimate of 15 ppm when measured in 1976, they assumed that exposure in that job in 1945 was also 15 ppm. While this procedure might appear to be reasonable as a first approximation in a retrospective study, alternatives exist to the assumption that exposure levels did not change. Other alternatives might include the assumption that the exposure level continued at a certain measured level until observed to be lower, or that the decrease (or increase) in level progressed uniformly from one period of measurement to another.
Crump and Allen (19) developed an alternative exposure assumption in an analysis of the industrial hygiene data in a report for OSHA. Crump and Allen estimated both a cumulative benzene exposure amount and a maximum or peak intensity benzene exposure level for each of the employees in Pliofilm production. To (19) provide independent data that permit determining which of the two assessments most likely represents the actual benzene exposures. The reports by Kipen et al. (21, 22) analyzing hematology studies of the workers at plant 1 does provide some insight.
Because benzene causes hematotoxicity as demonstrated by reduced blood cell counts, complete blood cell counts were frequently conducted on Pliofilm workers. The hematology data from plant 1 were analyzed by Kipen, Cody, and Goldstein (22), who identified the blood counts of individual workers, determined from their work histories their job assignments at the time the blood specimens were taken, and specified the benzene exposure level that either Crump 
Quantitative Risk Analysis
For developing a quantitative risk assessment for benzene based on the mortality data of the Ohio Pliofilm study (5), dispute exists over which worker population, which exposure estimates, and which leukemias should be used.
The NIOSH study by Rinsky et al. (5) limited the population to the Pliofilm workers who worked in the wet side section through 1965. Crump and Allen (19) used as their study population all known workers in the Pliofilm operation through 1965, including both the workers from the wet side and the workers from the dry side of the Pliofilm operation. We concur with Crump and Allen that for a quantitative risk analysis the studied cohort should include all those in Pliofilm manufacture, and not just those from the wet side. Inclusion of as full a spectrum of exposure as feasible increases the robustness and reduces the uncertainty in applications of the derived risk estimate. Exclusion of the dry side workers specifically diminishes the low end of the exposure spectrum.
Rinsky et al. assumed, in the absence of exposure data, that exposure over time was constant on an absolute scale; Crump and Allen assumed, in the absence of exposure data, that exposure over time was constant on a relative scale, relative to the occupational benzene standard of the time. Rinsky et al. concentrated on the cumulative benzene exposure; Crump and Allen explored the interpretation of both the cumulative benzene exposure estimates and the peak benzene exposure estimates. We would have explored a number of different exposure assumptions, as indicated, and for both peak and cumulative exposures. With respect to exposure data, we would have given preference to the Crump and Allen assumptions, based on the analysis by Kipen et al. (21) of the hematology data at plant 1.
Both assessments used the exposure data from location 1 to serve as a surrogate measure of exposure at location 2. If the benzene exposure is thought to be the critical determinant of risk, we find it difficult to accept that the benzene exposure levels at location 2, where all of the AML cases occurred, could have been the same as the exposure levels at location 1, where no AML cases occurred. We would have reported the risk analysis of each location separately.
Both Rinsky et al. and Crump and Allen incorporated all leukemias in their analyses. We would have reported separately the analysis of risk of acute myeloid leukemia (AML). Based on the observations in the larger studies of leukemia in benzene-exposed workers, we believe that evaluation of the risk of benzene-associated leukemia should specifically target upon AML. The calculated risk values would thus become more significant, both statistically and biologically.
The most appropriate study population would have consisted of all persons who ever worked in the Pliofilm operation. Unfortunately, the personnel records no longer exist for persons who worked in the Pliofilm operation in plant 2A and terminated their Pliofilm assignment prior to 1945. Therefore, those individuals cannot be included in the study population. In view of this exclusion, the population is best analyzed as a combination of a crosssectional study cohort and an employment incidence cohort. We would have separately analyzed the risks for the employment incidence cohort from that of the crosssectional cohort and have discussed the differences in observations.
Separating the analysis into multiple strata is a problem when only a few cases (6 AML, 2 CML, and 1 MoL) of leukemia have been observed. Nonetheless, it is important to observe whether the cases (and the risks) do concentrate within the most rigorously defined cohort or in its periphery. velopment of a significant excess risk of disease mortality. As a model, the cumulative leukemia risk (using all 9 leukemia cases) with benzene exposure expressed by peak exposure experienced by workers is presented for sequentially higher peak levels of benzene exposure. This particular graph shows peak benzene exposure levels according to Rinsky's (5) exposure assumptions. The cohort is defined according to Crump and Allen's (19) criteria. The three lines represent sequentially the cumulative number of cases of leukemia observed, the cumulative number of cases of leukemia expected, and the 95% lower confidence limit of the observed number of leukemia cases. A statistically significant excess of leukemia cases has been observed when the 95% lower confidence limit is greater than the cumulative expected. It is not until the last two exposure levels are included that there is a significant excess of leukemia observed among the benzene exposed workers. Thus, if the NIOSH assumptions of Rinsky (5) are used, this occurs at a peak benzene level greater than 40 ppm (Fig. 8) . If the exposure assumptions of Crump and Allen (19) are used, a statistically significant excess of leukemia cases is observed only when workers with exposures above 250 ppm are included (Fig.   9 ). Risk analysis for all leukemia classes based on both the exposure estimates and the cohort assumptions of Rinsky (5) would lead to the conclusion that a significant excess risk of leukemia was not observed until the study population included those with a peak benzene exposure of greater than 20 ppm or an estimated cumulative benzene exposure of greater than 250 ppm-years (Table 4) . Similar analyses based on the exposure estimates of Crump and Allen (19) and applied to all the studied workers at the plants lead to the conclusion that a significant excess risk of leukemia was not observed for those in the study group who had an estimated peak benzene exposure of less than 250 ppm or an estimated cumulative benzene exposure of less than 450 ppm-years ( Table 4 ). Assuming that these exposures occurred over a 40-year worklife, the Rinsky assumptions using this model would reach the conclusion that a statistically significant leukemia risk existed with peak benzene exposure over 20 ppm and a worklife average exposure over 6 ppm (250 ppm-yrs/40 years = 6.25 ppm). Similarly, the Crump assumptions using the same model would conclude that a statistically significant leukemia risk existed with peak benzene exposure over 250 ppm and a worklife average exposure over 11 ppm (450 ppm-yr/40 years = 11.25 ppm). Thus, the determination as to whether the previous benzene standard of 10 ppm included a significant leukemia risk is markedly dependent upon the methodological assumptions made in analyzing the data.
Graphical Risk Analysis

Conclusions
Available data strongly support the conclusion that AML can be caused by excessive benzene exposure. This is a consistent observation among all recent studies with the exception of that of Wong (14) .
There is no consistent evidence for production of (19) exposure estimates. Furthermore, the risk ratio does not appear to stay constant after a latent period, but appears to fall with time.
The nonlinearity of risk with exposure dose, the observation of pancytopenia prior to leukemia, and the latent period are all consistent with leukemia as an indirect effect of benzene.
If the data are to be used for quantitative assessment, the analysis should be limited to AML cases, the surrogate nature of the exposure data should be noted, and the observation that the excess cases of AML all have attributed cumulative benzene exposures of 250 to 650 ppmyears should be prominently observed.
We propose that future assessments of leukemic risk from benzene exposure be based on the distribution pattern of AML alone, as that is the sentinel neoplastic disease associated with excess benzene exposure. This concept is consistent with the assessment of Goldstein (8) and with the studies of Vigliani (3), Aksoy (2), Rinsky (5), Bond (13) , and Yin (4).
